DAWN PE Ratio & Valuation, Is DAWN Overvalued

Historical Valuation

Day One Biopharmaceuticals Inc (DAWN) is now in the Overvalued zone, suggesting that its current forward PS ratio of 4.25 is considered Overvalued compared with the five-year average of -8.34. The fair price of Day One Biopharmaceuticals Inc (DAWN) is between 16.97 to 20.24 according to relative valuation method. Compared to the current price of 21.44 USD , Day One Biopharmaceuticals Inc By Overvalued By 5.92%.

Relative Value

Fair Zone

16.97-20.24

Current Price：21.44

5.92%

Overvalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Day One Biopharmaceuticals Inc (DAWN) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Day One Biopharmaceuticals Inc (DAWN) has a current Price-to-Book (P/B) ratio of 2.02. Compared to its 3-year average P/B ratio of 2.79, the current P/B ratio is approximately -27.82% higher. Relative to its 5-year average P/B ratio of 3.13, the current P/B ratio is about -35.57% higher. Day One Biopharmaceuticals Inc (DAWN) has a Forward Free Cash Flow (FCF) yield of approximately -13.36%. Compared to its 3-year average FCF yield of -11.56%, the current FCF yield is approximately 15.57% lower. Relative to its 5-year average FCF yield of -9.13%, the current FCF yield is about 46.21% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for DAWN competitors is 2.13, providing a benchmark for relative valuation. Day One Biopharmaceuticals Inc Corp (DAWN.O) exhibits a P/S ratio of --, which is -100% above the industry average. Given its robust revenue growth of 83.92%, this premium appears sustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of DAWN increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of DAWN in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is DAWN currently overvalued or undervalued?

Day One Biopharmaceuticals Inc (DAWN) is now in the Overvalued zone, suggesting that its current forward PS ratio of 4.25 is considered Overvalued compared with the five-year average of -8.34. The fair price of Day One Biopharmaceuticals Inc (DAWN) is between 16.97 to 20.24 according to relative valuation method. Compared to the current price of 21.44 USD, Day One Biopharmaceuticals Inc is Overvalued By 5.92%.

What is Day One Biopharmaceuticals Inc (DAWN) fair value?

DAWN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Day One Biopharmaceuticals Inc (DAWN) is between 16.97 to 20.24 according to relative valuation method.

How does DAWN's valuation metrics compare to the industry average?

The average P/S ratio for DAWN's competitors is 2.13, providing a benchmark for relative valuation. Day One Biopharmaceuticals Inc Corp (DAWN) exhibits a P/S ratio of --, which is -100.00% above the industry average. Given its robust revenue growth of 83.92%, this premium appears sustainable.

What is the current P/B ratio for Day One Biopharmaceuticals Inc (DAWN) as of Mar 31 2026?

As of Mar 31 2026, Day One Biopharmaceuticals Inc (DAWN) has a P/B ratio of 2.02. This indicates that the market values DAWN at 2.02 times its book value.

What is the current FCF Yield for Day One Biopharmaceuticals Inc (DAWN) as of Mar 31 2026?

As of Mar 31 2026, Day One Biopharmaceuticals Inc (DAWN) has a FCF Yield of -13.36%. This means that for every dollar of Day One Biopharmaceuticals Inc's market capitalization, the company generates -13.36 cents in free cash flow.

What is the current Forward P/E ratio for Day One Biopharmaceuticals Inc (DAWN) as of Mar 31 2026?

As of Mar 31 2026, Day One Biopharmaceuticals Inc (DAWN) has a Forward P/E ratio of -14.73. This means the market is willing to pay $-14.73 for every dollar of Day One Biopharmaceuticals Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Day One Biopharmaceuticals Inc (DAWN) as of Mar 31 2026?

As of Mar 31 2026, Day One Biopharmaceuticals Inc (DAWN) has a Forward P/S ratio of 4.25. This means the market is valuing DAWN at $4.25 for every dollar of expected revenue over the next 12 months.

DAWN Valuation